Successful Implementation of Newborn Screening for Hemoglobin Disorders in the Philippines

International Journal of Neonatal Screening

Bradford L. Therrell¹  Maria Paz Virginia K. Otayza²  Bernadette C. Halili-Mendoza³  Conchita G. Abarquez⁴  Anna Lea G. Elizaga⁵  Alma P. Andal⁶  J. Edgar Winston C. Posecion⁷  Carmencita D. Padilla⁸  Maria Beatriz P. Gepte⁸  Charity M. Jomento⁸  Ebner Bon G. Maceda⁸  Ma. Elouisa L. Reyes⁸  Maria Melanie Liberty B. Alcausin⁸  Reynaldo C. de Castro⁸  Riza Concordia N. Suarez⁸  Carolyn C. Hoppe⁹ 

[1] National Newborn Screening and Global Resource Center, Austin, TX 78759, USA;Newborn Center—Northern Luzon, Mariano Marcos Memorial Hospital and Medical Center, Batac City 2906, Philippines;Newborn Screening Center—Central Luzon, Angeles City University Foundation Medical Center, Angeles City 2009, Philippines;Newborn Screening Center—Mindanao, Southern Philippine Medical Center, Davao 8000, Philippines;Newborn Screening Center—National Institutes of Health, Quezon City 1101, Philippines;Newborn Screening Center—Southern Luzon, Daniel O. Mercado Medical Center, Tanauan City 4232, Philippines;Newborn Screening Center—Visayas, West Visayas State University Medical Center, Iloilo City 5000, Philippines;Newborn Screening Reference Center, National Institutes of Health, University of the Philippines Manila, Manila 1000, Philippines;UCSF Benioff Children’s Hospital Oakland, Oakland, CA 94609, USA;

关键词: newborn screening;    thalassemia;    hemoglobinopathy;    HPLC;    Philippines;   

DOI  :  10.3390/ijns7020030

来源: DOAJ

【 摘 要 】

The Philippine newborn bloodspot screening (NBS) program began in 1996 with 24 hospitals and was formalized by legislation in 2004. The NBS panel was recently expanded to include a number of additional hereditary congenital conditions. Expertise and experiences from other NBS programs already screening for hemoglobinopathies were essential to its successful integration into the ongoing dried bloodspot NBS program in the Philippines. Building on clinical experiences and population data from Filipinos born in California, USA, hemoglobinopathies (including thalassemias) were selected for inclusion in the expanded screening panel. Hemoglobinopathy NBS, using high performance liquid chromatography, was implemented in a stepwise manner into the seven regional NBS screening laboratories. A central university laboratory provides confirmatory testing using both capillary electrophoresis and molecular methodologies. NBS results indicating carriers are followed up with educational fact sheets, while results of presumptive disease are referred for confirmatory testing and follow-up with a hematologist. Long-term care is provided through newborn screening continuity clinics across the country. Hemoglobinopathy NBS is now included in the national insurance package and screening uptake continues to increase nationally, exceeding 90% of all newborns in 7400+ hospitals and birthing centers nationwide prior to the COVID-19 pandemic.

【 授权许可】

Unknown